Moreover, our group has previously demonstrated that administration of DNMT inhibitors (DNMTI) induces reprogramming of refractory DLBCL cells resulting in recovery of sensitivity toward DNA damaging agents [7]. This evidence concerns the gene DNMT1 and diffuse large B-cell lymphoma.